News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,764 Results
Type
Article (39728)
Company Profile (247)
Press Release (659789)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204184)
Career Advice (2008)
Deals (35420)
Drug Delivery (95)
Drug Development (81049)
Employer Resources (172)
FDA (16189)
Job Trends (14864)
News (345219)
Policy (32543)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49444)
ALS (93)
Alzheimer's disease (1382)
Antibody-drug conjugate (ADC) (132)
Approvals (16186)
Artificial intelligence (261)
Autoimmune disease (22)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (175)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (290)
Cancer (2306)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (153)
Cell therapy (432)
Cervical cancer (20)
Clinical research (66065)
Collaboration (853)
Company closure (2)
Compensation (557)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (249)
Cystic fibrosis (101)
Data (2297)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6378)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (102)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (86981)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112611)
Executive appointments (737)
FDA (17552)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (764)
Gene editing (109)
Generative AI (19)
Gene therapy (308)
GLP-1 (716)
Government (4427)
Grass and pollen (4)
Guidances (150)
Healthcare (18818)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (121)
Indications (29)
Infectious disease (2734)
Inflammatory bowel disease (143)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (97)
Interviews (312)
IPO (16522)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (324)
Lymphoma (156)
Machine learning (9)
Management (58)
Manufacturing (322)
MASH (73)
Medical device (13382)
Medtech (13387)
Mergers & acquisitions (19466)
Metabolic disorders (702)
Multiple sclerosis (82)
NASH (16)
Neurodegenerative disease (91)
Neuropsychiatric disorders (27)
Neuroscience (1929)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (40)
Obesity (371)
Opinion (204)
Ovarian cancer (80)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (150)
Partnered (21)
Patents (241)
Patient recruitment (115)
Peanut (46)
People (57336)
Pharmaceutical (63)
Pharmacy benefit managers (19)
Phase I (20579)
Phase II (29101)
Phase III (21668)
Pipeline (1344)
Policy (146)
Postmarket research (2563)
Preclinical (8755)
Press Release (64)
Prostate cancer (107)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (382)
Real estate (5907)
Recruiting (65)
Regulatory (22321)
Reports (47)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (70)
Series A (131)
Series B (87)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3579)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (48)
The Weekly (30)
Vaccines (697)
Venture capitalists (42)
Weight loss (236)
Women's health (36)
Worklife (16)
Date
Today (82)
Last 7 days (927)
Last 30 days (3040)
Last 365 days (32427)
2025 (11662)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37872)
Australia (6190)
California (6366)
Canada (2059)
China (532)
Colorado (271)
Connecticut (278)
Delaware (156)
Europe (81374)
Florida (946)
Georgia (212)
Idaho (57)
Illinois (545)
India (25)
Indiana (318)
Iowa (11)
Japan (171)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (918)
Massachusetts (4727)
Michigan (223)
Minnesota (401)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (67)
New Hampshire (63)
New Jersey (1782)
New Mexico (28)
New York (1794)
North Carolina (985)
North Dakota (8)
Northern California (2801)
Ohio (208)
Oklahoma (14)
Oregon (34)
Pennsylvania (1417)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (25)
South Dakota (1)
Southern California (2398)
Tennessee (105)
Texas (944)
United States (23852)
Utah (188)
Virginia (151)
Washington D.C. (64)
Washington State (561)
West Virginia (3)
Wisconsin (56)
699,764 Results for "surrozen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
April 1, 2025
·
11 min read
Press Releases
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
March 25, 2025
·
11 min read
Press Releases
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
November 5, 2024
·
5 min read
Business
Surrozen Provides First Quarter 2024 Financial Results and Business Update
Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, provided first quarter 2024 financial results and business updates.
May 8, 2024
·
11 min read
Drug Development
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first patient has been dosed in its Phase 1b clinical trial for SZN-043 in patients with severe alcohol-associated hepatitis.
June 4, 2024
·
7 min read
Biotech Bay
Surrozen Publishes Study in ‘Respiratory Research’ Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen, Inc. (Nasdaq: SRZN) announced today publication of data in Respiratory Research highlighting the potential for Surrozen’s Wnt mimetic technologies to treat serious lung diseases like idiopathic pulmonary fibrosis (IPF) https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-024-02786-2.
April 3, 2024
·
8 min read
Press Releases
Surrozen to Present at Upcoming Healthcare Investor Conferences
November 7, 2024
·
4 min read
Biotech Bay
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN) announced today that preclinical data highlighting the potential for Surrozen’s antibody-based Wnt mimetic technologies to treat cornea endothelial damage and Dry Eye Disease (DED) were presented on May 7, 2024 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle.
May 9, 2024
·
9 min read
Biotech Bay
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
Surrozen, Inc. announced publication of data in eLife highlighting the potential to enhance Wnt-signal activation in new targeted SWEETS bispecific antibodies which utilize a unique protein degradation platform that provides alternatives for future clinical applications.
June 12, 2024
·
7 min read
Drug Development
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, provided an update on the Phase 1a clinical trial of SZN-043 in healthy volunteers and patients with cirrhosis.
April 1, 2024
·
9 min read
1 of 69,977
Next
